Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options (Q35029802)

5 August 2017

1 reference

title

Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options (English)

1 reference

5 August 2017

0 references

Ken Fujioka

1

1 reference

5 August 2017

1 December 2002

1 reference

5 August 2017

1 reference

5 August 2017

10 Suppl 2

1 reference

5 August 2017

116S-123S

1 reference

Food provision as a strategy to promote weight loss

5 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Use of very low-calorie diet in preoperative weight loss: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Popular diets: a scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

The effects of different percentages of dietary fat intake, exercise, and calorie restriction on body composition and body weight in obese females

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Dietary protein and weight reduction: a statement for healthcare professionals from the Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Exercise in weight management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Successful weight loss maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Relapse prevention training and problem-solving therapy in the long-term management of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Current concepts in the pharmacological management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Comparison of continuous and intermittent anorectic therapy in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Absence of cardiac valve dysfunction in obese patients treated with sibutramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Weight loss with topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Influence of topiramate in the regulation of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Topiramate for binge-eating disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Treatment of affective disorder and obesity with topiramate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Orlistat, a new lipase inhibitor for the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Orlistat--a novel weight loss therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Use of nonprescription weight loss products: results from a multistate survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Vertical banded gastroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Bariatric surgery for morbid obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Mood stabilization and weight loss with topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Medical management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

The role of dietary fat in the prevention and treatment of obesity. Efficacy and safety of low-fat diets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Evaluation of a modified cognitive-behavioural programme for weight management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Pharmacological treatment of obesity: present status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Orlistat in the long-term treatment of obesity in primary care settings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Current pharmacological approaches to the treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

Behavioral choice treatment promotes continuing weight loss: preliminary results of a cognitive-behavioral decision-based treatment for obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.204

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/OBY.2002.204

1 reference

5 August 2017

1 reference

PubMed ID

12490660